PanGIA Biotech, Inc. ("PanGIA") announced a peer-reviewed clinical study published in Diagnostics, "Urine-Based Machine ...

Researchers are developing genomic screening tools to tailor radiation dose and hormone therapy for prostate cancer patients, ...

Back in the ’90s, a promotion ran about the “crazy ones,” which conflated a popular computer brand with protean figures such ...

Chris is a writer and editor with over 10 years of experience covering games and has a bachelor's degree in History from the University of Central Lancashire. He's mainly focused on guides, but has ...

VCYT rides on Afirma and Decipher growth with strong earnings beat and liquidity, but macro pressures and rising competition cloud its near-term outlook.

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). The phase 3 Talapro-3 trial met its primary ...

J&J JNJ announced that the European Commission has approved its precision therapy, Akeega (niraparib and abiraterone acetate dual action tablet), for expanded use in prostate cancer. The regulatory ...

Lung cancer is the leading cause of death from cancer. It kills more people in the U.S. than breast, prostate, and colon ...

What if a medicine you thought of as “old news” suddenly showed up in new research with fresh benefits that might stretch well beyond its original purpose? That’s exactly the twist happening with a ...